Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive agomelatine in adults with major depressive disorder
ACTRN12621000601831Phase 4Completed
- Sponsor
- Alto Neuroscience
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agomelatine in major depressive disorder (MDD), sponsored by Alto Neuroscience. Primary endpoint: Neurobiological effects assessed by EEG. Started Jun 2021; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12621000601831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000601831.